3, 3'-Diindolylmethane enhances the effectiveness of herceptin against HER-2/neu-expressing breast cancer cells.
Herceptin failure is a major clinical problem in breast cancer. A subset of breast cancer patients with high HER-2/neu levels eventually experience metastatic disease progression when treated with Herceptin as a single agent. Mechanistic details of development of this aggressive disease are not clea...
Guardado en:
Autores principales: | Aamir Ahmad, Shadan Ali, Alia Ahmed, Azfur S Ali, Avraham Raz, Wael A Sakr, K M Wahidur Rahman |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/132db317f8b44411888892d7b099a6a9 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Utility of Serum HER-2/ neu in Prediction of Tissue HER-2 /neu Status of Primary Breast Cancer
por: Maral Mokhtari, et al.
Publicado: (2021) -
HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer.
por: Merel Gijsen, et al.
Publicado: (2010) -
Cancer biomarker HER-2/neu in breast cancer in Indian women
por: Singhai R, et al.
Publicado: (2011) -
Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
por: Salkeni MA, et al.
Publicado: (2021) -
Ultrasound-triggered herceptin liposomes for breast cancer therapy
por: Amal Elamir, et al.
Publicado: (2021)